巩膜睫状体光凝术治疗恶性青光眼睫状环阻滞解除后高眼压

目的:探讨经巩膜睫状体光凝治疗恶性青光眼睫状环阻滞解除后高眼压的短期与中期有效性和安全性。方法:回顾性研究。收集2016-10/2019-10恶性青光眼睫状环阻滞解除后眼压仍高的患者14例14眼,采用810nm半导体二极管激光经巩膜睫状体光凝术治疗,随访8.36±5.18mo,观察手术前后最佳矫正视力(BCVA)、眼压及并发症情况。结果:治疗后末次随访眼压13.60±3.50mmHg较术前40.53±7.14mmHg有差异(P<0.05);术后末次随访BCVA与术前比较无差异(P>0.05),所有患者至末次随访时无严重并发症。结论:采用810nm半导体二极管激光经巩膜睫状体光凝术治疗恶性青光眼疗效确切,操作简便,并发症少,可有效降低眼压,且对术后BCVA损害较小。     

810nm激光睫状体光凝治疗难治性青光眼的疗效

目的:探讨810nm激光经巩膜睫状体光凝治疗难治性青光眼的临床疗效。方法:对25例30眼难治性青光眼患者行810nm激光经巩膜睫状体光凝术,术后随访3mo,分析术后眼压、疼痛感、视力、并发症等情况。结果:术后随访期间全部患者眼痛症状均缓解。术前平均眼压为50.42±2.50mmHg,末次随访时平均眼压15.95±4.19mmHg,术后眼压与术前相比,差异有显著统计学意义(P<0.01)。光凝术后2眼(6.7%)视力提高,24眼(80.0%)视力无变化,4眼(13.3%)视力下降。术后前房渗出12眼(40.0%),前房积血3眼(10.0%),玻璃体积血1眼(3.3%),药物治疗后消失。结论:810nm激光经巩膜睫状体光凝术是治疗难治性青光眼的有效方法,能显著降低眼压,减少患者痛苦,并发症少。     

二极管激光经巩膜睫状体光凝术治疗急性闭角型青光眼持续性高眼压

目的 评价二极管激光经巩膜睫状体光凝术治疗急性闭角型青光眼持续性高眼压的疗效.方法 40例(40眼)原发性急性闭角型青光眼急性大发作患者,经72h应用多种降眼压药物治疗后眼压仍在40mmHg(1kPa=7.5 mmHg)以上,行二极管激光经巩膜睫状体光凝术.平均光凝能量(2290.00 ±149.01)mW,平均光凝点数(21.73±3.50)点.术后随访6～12个月,观察患者症状、眼压、视力变化和术后并发症等.结果 术后随访期间全部患者眼痛症状均缓解.术前平均眼压为(52.56±7.31)mmHg,末次随访时平均眼压(14.18±4.53)mmHg,术后眼压与术前相比,差异有显著统计学意义(P<0.001).术后平均视力(0.127 0±0.1650)较术前(0.033 4±0.0322)提高,差异也有显著统计学意义(P<0.01).光凝术后25眼(62.5%)视力提高,8眼(20.0%)视力无变化,7眼(17.5%)视力下降.术后前房炎症反应伴前房渗出3例,前房出血1例,药物治疗后消失.结论 二极管激光经巩膜睫状体光凝术治疗原发性急性闭角型青光眼持续性高眼压,疗效确切,可降低眼压,缓解疼痛,并发症少.     

经巩膜睫状体光凝治疗难治性青光眼的临床观察

目的:评价半导体激光经巩膜睫状体光凝术治疗难治性青光眼的效果。方法:回顾性分析55例56眼难治性青光眼的临床资料,均行睫状体光凝,术后随访观察并记录眼压、视力、眼部自觉症状以及并发症,随访时间3mo以上。结果:术前平均眼压53.5±18.7mmHg,末次随访平均眼压为19.4±9.6mmHg,术后眼压与术前眼压相比,差别具有统计学意义(P<0.01)。术后44眼视力无变化,2眼视力提高,10眼视力下降;眼痛均消失或缓解;并发症少,主要有葡萄膜炎、前房出血等。结论:睫状体光凝能有效降低难治性青光眼患者的眼压,且并发症少。     

二极管激光经巩膜睫状体光凝术治疗先天性小眼球合并青光眼

目的：观察二极管激光经巩膜睫状体光凝术治疗先天性小眼球合并青光眼持续性高眼压的临床效果。 方法：回顾性自身对照研究,收集2009-01/2011-01在邢台眼科医院收治的先天性小眼球继发青光眼持续性高眼压并行二极管激光经巩膜睫状体光凝术的患者5例7眼。观察手术前后视力、眼压、并发症情况,并进行统计学处理。 结果：术后随访期间全部患者眼痛症状均缓解。术前平均眼压为52.56±7.31mmHg,术后1mo平均眼压17.8±47mmHg,6mo随访时平均眼压14.18±4.53mmHg,术后1mo及6mo眼压与术前相比,差异有显著统计学意义(P<0.01)。术后平均视力(0.127±0.165)较术前(0.0334±00322)提高,差异有显著统计学意义(P<0.01)。光凝术后5眼(71.4%)视力提高,2眼(28.6%)视力无变化,术后均有前房炎症反应伴前房渗出,药物治疗后消失。 结论：二极管激光经巩膜睫状体光凝术治疗先天性小眼球合并青光眼持续性高眼压,疗效确切,可降低眼压,缓解疼痛,并发症少。     

新生血管性青光眼不同手术疗法的疗效对比

目的:对比经巩膜睫状体光凝术和睫状体冷凝术对于新生血管性青光眼的疗效。方法:选取2006年在我院住院的38例43眼新生血管性青光眼患者,一组采用常规睫状体冷凝术18眼,另一组采用810nm激光经巩膜睫状体光凝术治疗25眼,术后处理相同,术后12wk随诊期内观察患者眼部表现、视力、眼压情况。结果:睫状体冷凝组11眼(61%)、睫状体光凝组20眼(80%)术后3mo眼压稳定于11~24mmHg之间,各组术前、后眼压对比,差异均有高度统计学意义(P=0.000);组间术后眼压对比,差异无统计学意义(P=0.669)。睫状体冷凝组10眼(56%)、睫状体光凝组21眼(84%)视力保存,差异有统计学意义(P=0.040)。所有患者术后2wk虹膜新生血管开始逐渐减少,睫状体冷凝患者术后均有明显球结膜充血水肿,并颜面浮肿、眼痛、头痛;睫状体光凝患者术后仅有轻度球结膜混合充血,无颜面部浮肿、头痛及眼痛、前房出血。结论:治疗新生血管性青光眼,睫状体冷凝术及经睫状体激光光凝术控制眼压效果确切;而睫状体激光光凝术手术具有视力保存率高、并发症少,患者术后痛苦少等优点。     

二极管激光经巩膜睫状体光凝术治疗难治性青光眼

目的:研究二极管激光经巩膜睫状体光凝术治疗难治性青光眼的有效性及激光治疗参数。方法:对我院收治的50例50眼晚期难治性青光眼患者行二极管激光经巩膜睫状体光凝术,记录每位患者所用能量,击射范围,光凝点数,爆破点数,观察患者治疗前后的眼压、眼部症状,视力、裂隙灯观察眼前节的改变和并发症等。结果:术后平均眼压(18.50±2.50)mmHg,术后眼压较术前明显下降(P<0.01)。术后46眼疼痛明显减轻,术前术后眼压差值与击射能量的相关性不高;眼压下降值与击射范围、击射点数呈正相关性,眼压下降值与爆破点数显著相关,呈正相关性。结论:二极管激光经巩膜睫状体光凝术治疗难治性青光眼是一种安全有效的方法,激光治疗参数需根据术前眼压、不同类型青光眼进行设计。     

二极管激光经巩膜睫状体光凝术治疗难治性青光眼

目的 观察二极管激光经巩膜睫状体光凝术治疗难治性青光眼的临床疗效.方法 回顾性分析北京同仁医院2007年9月至2008年8月107例(110眼)难治性晚期青光眼患者临床资料,均行二极管睫状体光凝,分析术后眼压、疼痛感、视力、并发症等情况.结果 术后第1天平均眼压(15.90±12.30)mmHg(1 kPa=7.5 mmHg),术后1周平均眼压(14.70±5.21)mmHg,术后1个月平均眼压(14.02±9.50)mmHg,术后3个月平均眼压(14.51±11.30)mmHg,术前与术后第1天、1周、1个月及3个月眼压差异均有统计学意义(均为P<0.01).术后89眼(80.9%)视力不变,17眼(15.5%)视力下降,4眼(3.6%)视力提高.83.6%的患者眼痛症状明显缓解或消失.术后发生前房渗出12眼(10.9%),前房积血6眼(5.4%),玻璃体积血2眼(1.8%),巩膜溶解2眼(1.8%),巩膜穿孔1眼(0.9%).结论 二极管激光经巩膜睫状体光凝术是治疗难治性晚期青光眼的有效方法,能显著降低眼压,减少患者痛苦,并发症少,可重复治疗.     

半导体激光经巩膜睫状体光凝术治疗新生血管性青光眼的远期疗效

目的评价半导体激光经巩膜睫状体光凝术治疗新生血管性青光眼的远期疗效。方法回顾性分析71例（72眼）行半导体激光经巩膜睫状体光凝术的新生血管性青光眼,术前平均眼压为（56.2±12.0）mmHg（36～71mmHg,1kPa=7.5mmHg）,术后随访6个月～5a,观察眼部自觉症状、眼压、视力及并发症。结果最后1次随访的平均眼压为（17.3±5.9）mmHg（13～32mmHg）,降压成功率为94.4%.2眼发生眼球萎缩。视力提高7眼,视力无变化55眼,视力下降10眼。结论半导体激光经巩膜睫状体光凝术是一种简单、安全、有效的治疗新生血管性青光眼的方法。     

玻璃体切割联合睫状突光凝术治疗新生血管性青光眼

目的：对需行玻璃体手术且并发新生血管性青光眼的患者进行眼内睫状突光凝术,观察术后眼压控制效果及手术安全性。 方法：回顾12例14眼新生血管性青光眼患者,分别继发于糖尿病性视网膜病变、视网膜脱离术后及眼外伤。本术式主要是在玻璃体切除术后立即采用眼内光凝导管直接对睫状突进行光凝,直到睫状突出现白色萎缩或爆破音为止,曝光时间0.1~0.2ms,能量300~500mW。术后随访6mo,分别于术后1wk;1,6mo观察14只新生血管性青光眼的眼压和并发症情况。 结果：本研究发现11眼眼压出现明显下降至正常范围之内。光凝术后1wk平均眼压为16.7±14.4mmHg,1mo为15.7±8.8mmHg,6mo为12.9±4.5mmHg,与治疗前（39.6±10.0mmHg）相比差异具有统计学意义（P〈0.01）。随访期间3眼再次出现眼压升高,因其不具备再次玻璃体手术适应证而给予了经巩膜或内窥镜下睫状体突光凝术。随访期间患眼未出现眼内炎及眼球萎缩等并发症。 结论：眼内睫状突光凝与玻璃体手术同时进行,可同时处理原发疾病和青光眼。该术式可在直视下准确光凝睫状突,对治疗需要玻璃体切除术的新生血管性青光眼是一种较安全有效的方法。     

青光眼阀植入联合广泛视网膜光凝治疗新生血管性青光眼

目的探讨青光眼阀植入联合广泛视网膜光凝治疗新生血管性青光跟的疗效。方法回顾性分析了16例（16眼）新生血管性青光眼接受青光眼阀植入及广泛视网膜光凝治疗的效果,其中6眼同时行晶状体摘出,4眼同时行晶状体摘出、玻璃体切除。术后随访8～24个月,分析术前与术后的眼压、视力、虹膜表面新生血管及术后并发症。结果术前平均眼压：（45．90±7．84）mmHg（31—67mmHg）。手术后平均眼压：1周为（14．15±3．35）mmHg,2周为（16．30±4．20）mmHg,4周为（17．85±3．15）mmHg,12周为（15．60±2．75）mmHg,末次复诊眼压（18．50±3．75）mmHg。术后末次复诊视力提高11眼,视力不变5眼,无视力下降或丧失者。术后并发症主要有：前房积血3眼,前房形成迟缓及低眼压6眼,引流管堵塞1眼,脉络膜部分脱离1眼。16眼虹膜新生血管全部或部分消退,临床症状缓解。结论青光眼阀植入联合广泛视网膜光凝术治疗新生血管性青光眼既能及时降低眼压,又能拯救或提高视力,是治疗新生血管性青光眼的一种安全而有效的方法。     

Audible pops during cyclodiode procedures.

PURPOSE: This study was conducted to determine the incidence of intraocular uveal microexplosions ("pops") during contact diode laser transscleral cyclophotocoagulation (cyclodiode) and to analyze the influence of pop occurrence on results and postoperative complications. METHODS: Cyclodiode treatment (1.5-2 W x 2 seconds over 270 degrees) was performed in 43 consecutive patients (43 eyes) with uncontrolled glaucoma who had not undergone previous ciliary ablation. Mean duration of follow-up evaluation was 12.7 months (range, 9-18 months). These eyes included 31 seeing eyes, in which intraocular pressure (IOP) reduction was indicated to preserve visual acuity (therapeutic group) and 12 blind eyes, in which IOP reduction was advisable to relieve pain (palliative group). Success was defined as a final IOP > or = 5 mmHg and < or = 21 mmHg in seeing eyes, and as the resolution of pain in blind eyes. Potential factors evaluated for intraoperative pop occurrence included patient age, gender, iris color, glaucoma diagnosis, preoperative IOP, and number of previous surgical procedures used to treat glaucoma. RESULTS: In the group receiving therapeutic treatment, mean +/- standard deviation (SD) IOP was 41.8 +/- 12.7 mmHg before surgery and 19.2 +/- 8.3 mmHg after surgery; the success rate in this group was 83.9%. In the group receiving palliative treatment, mean IOP was 55.4 +/- 13.7 mmHg before surgery and 21.1 +/- 13.4 mmHg after surgery; success rate was 83.3% in this group. Intraoperative microdisruptions occurred in 48.8% of the cases during the first laser application; 67.5% of these occurred in the superior half of the eye. No significant difference in rate of intraoperative pop was observed between patients after one cyclodiode session and those eyes that underwent additional sessions. Mean baseline IOP was significantly higher in patients with intraoperative occurrence of pops. An audible pop was more common in the group undergoing palliative treatment. Intraoperative occurrence of pops was associated with a greater severity of postoperative iridocyclitis. All patients with postoperative hyphema also had pops during surgery. No significant difference in the success rate was found between patients in whom intraoperative pops did and did not occur. CONCLUSION: Choroidal vaporization is significantly more common in patients with higher baseline IOP. Occurrence of pops also is associated with more severe postoperative inflammation and with a greater risk of postoperative hyphema.     

不同方法联合治疗新生血管性青光眼的临床观察

目的:观察不同方法[降眼压药物+玻璃体腔注射雷珠单抗+复合式小梁切除+ 全视网膜光凝(PRP)]联合治疗新生血管性青光眼(neovascular glaucoma,NVG)的疗效.方法:回顾性非随机临床对照研究.新生血管性青光眼患者24例24眼纳入研究,经降眼压药物治疗后,7眼正常眼压,17眼高眼压.所有患者均行玻璃体腔注射雷珠单抗 0.50mg/0.05mL,7d后行复合式小梁切除术.复合式小梁切除术后予以全视网膜光凝.术后随访6~18mo,观察联合治疗后虹膜新生血管消退时间、眼压、视力变化,术中术后并发症以及滤过泡情况.结果:所有患者玻璃体腔注射雷珠单抗后,虹膜新生血管1wk内完全消退.治疗前平均眼压41.38±3.16mmHg,治疗后6mo平均眼压12.69±1.52mmHg,两者比较有统计学差异(F=25.592,P<0.05).治疗前最佳矫正视力>0.1者3眼,视力0.01~0.1者10眼,无光感~指数者11眼,治疗后最佳矫正视力>0.1者5眼,视力0.01~0.1者16眼,无光感~指数者3眼,差异有统计学意义(Z=-2.201,P<0.05) .结论:不同方法联合治疗NVG患者能有效地控制眼压,保护视功能.     

眼外伤玻璃体术后青光眼应用睫状体光凝联合前房穿刺治疗观察

目的 探讨经巩膜睫状体光凝联合前房穿刺术治疗眼外伤玻璃体切除术后难治性青光眼的效果.方法 回顾复杂性眼外伤玻璃体手术后难治性青光眼41例(41只眼),采用经巩膜睫状体光凝联合前房穿刺术治疗,术后随访3-12个月.结果 41只眼中,手术前眼压是(43.14±12.37)mmHg,术后最后一次随访眼压为(19.76±7.06)mmHg,手术后眼压明显下降,(t=6.5742,P＜0.001).5只眼视力略有提高,33只眼无变化,3只眼视力下降.术后1只眼眼球萎缩.结论 经巩膜睫状体光凝联合前房穿刺术是治疗眼外伤玻璃体手术后难治性青光眼一种安全有效的方法.

Abstract：

Objective To evaluate the clinical effects of transscleral diode laser cyclophotocoagulation and paracentesis of anterior chamber for traumatic refractory glaucoma following vitrectomy.Methods Forty-one cases (41 eyes) with traumatic refractory glaucoma following vitrectomy were received the transscleral diode laser cyclophotocoagulation and paracentesis of antenor chamber, the patients were followed three to twelve months. Results The intraocular pressure (IOP) were (43.14±12.37) mmHg before treatment. IOP were (19.76±7.06) mmHg in the last following-up. IOP was significantly decreased by this surgery (P <0.001). The visual acuity in following-up, 5 eyes was unproved, 33 stable and 3 eyes decreased. One eye was atrophiabulbi. Conclusions Transscleral diode laser cyclophotocoagulation and paracentesis of anterior chamber is a safe and effective treatment for traumatic refractory glaucoma following vitrectomy.     

经巩膜睫状体光凝术治疗难治性青光眼的效果

目的评价经巩膜睫状体光凝术(TCP)治疗难治性青光眼的效果。方法回顾性研究。对北京爱尔英智眼科医院2017年7月至2018年12月行TCP治疗的难治性青光眼73例(81只眼)的临床资料进行分析。观察手术前后眼压、降眼压药物使用种类、术中光凝情况和并发症的发生。术后随访6个月。结果术前眼压(35.0±8.8)mmHg(1mmHg=0.133 kPa);术前使用降眼压药物3(3,4)种;术中光凝能量(2027.00±235.88)mW、光凝范围238.0°±44.7°、光凝点数(31.00±7.17)个;术后1 d眼压为(18.67±7.13)mmHg,术后1个月眼压(18.50±8.28)mmHg,术后3个月眼压(19.25±6.79)mmHg,术前与术后各时间点眼压差异均有统计学意义(t=14.496、12.775、11.277、11.802,均P<0.05);术后使用降眼压药物0(0,1)种;术后视力不变65只眼(80.2%);各类型难治性青光眼手术成功率70.0%~87.5%;术后长期低眼压2只眼,眼球萎缩2只眼。结论TCP可有效治疗难治性青光眼,对继发性青光眼效果优于原发性青光眼。     

全视网膜光凝联合睫状突光凝治疗新生血管性青光眼的临床研究

目的评价氪多波长激光行全视网膜光凝联合睫状突光凝治疗新生血管性青光眼的临床疗效。方法新生血管性青光眼31例（31只眼）,分别多次氪多波长激光行全视网膜光凝联合睫状突光凝治疗。结果观察及随访1～12个月2,2只眼眼压〈21 mm Hg,成功率占70.96%,5只眼视力有提高,占16.13%,虹膜新生血管完全消退,达100%。未见眼球萎缩等严重并发症。结论氪多波长激光全视网膜光凝联合睫状突光凝治疗新生血管性青光眼是一种疗效确切、成功率高的治疗方法。     

Surgical management of chronic glaucoma in aphakia

The surgical management of glaucoma in aphakia has been limited by poor success in the control of intraocular pressure and serious postoperative complications that threaten vision. A consecutive series of trabeculectomy filtering procedures in aphakic eyes with a mean preoperative intraocular pressure of 38 mmHg was followed for an average of 26 months and revealed a 62% control of intraocular pressure at 21 mmHg or less. Five additional patients (24%) had pressures lower than 21 mmHg following digital massage. The complication of decreased visual acuity following surgery was significant but not directly related to the surgical procedure. Another patient population with glaucoma and aphakia with a mean preoperative pressure of 25 mmHg was treated with laser trabeculoplasty. In 12 of 15 patients (80%) intraocular pressure was lower than 22 mmHg for an average of eight months and did not require glaucoma surgery. There were no significant complications following this therapy and all patients retained preoperative level of visual acuity. In aphakic patients who have uncontrolled glaucoma on maximal medical therapy, surgery is indicated. We recommend the following approach to surgical management: (1) Laser treatment to the trabecular meshwork if the angle is open; (2) if this fails, or the angle is extensively closed, a trabeculectomy filtering procedure is suggested; (3) cyclocryotherapy has been effective in controlling pressure but the unpredictable loss of vision has prompted caution in seeing eyes; (4) cyclodialysis; and (5) transpupillary or transscleral treatment of the ciliary processes are additional modes of therapy. Improved results of surgical treatment for glaucoma and aphakia have been encouraging and should be used when maximal medical therapy is ineffective.     

应用MMC的Ahmed青光眼阀植入术联合全视网膜光凝治疗NVG

目的:探讨应用丝裂霉素C的Ahmed青光眼阀植入联合全视网膜光凝治疗新生血管性青光眼的临床疗效。方法:新生血管性青光眼26例26眼,应用丝裂霉素C的Ahmed青光眼阀植入术联合全视网膜光凝治疗。结果:随访12mo,成功:16例眼压<21mmHg(61.54%),无明显眼部刺激症状。术前眼压平均49.78±14.17mmHg,术后眼压下降到平均18.45±8.91mmHg。末次复诊视力提高14眼(53.85%),视力不变12眼,无视力下降或丧失者。26眼中虹膜新生血管全部消退21眼,部分消退5眼。术后并发症主要有:浅前房6眼(23.08%),前房少量积血3眼(11.54%),引流管内口堵塞2眼(7.69%),引流盘纤维包裹1眼(3.85%)。结论:应用丝裂霉素C的Ahmed青光眼阀植入联合全视网膜光凝术治疗新生血管性青光眼,既能及时降低眼压,又能拯救或提高视力,是治疗新生血管性青光眼的一种安全而有效的方法。